AI healthcare stocks surged on September 17, led by a more than 15% jump from drug design company Absci Corp and a nearly 15% gain from Tempus AI, the precision medicine firm backed by Cathie Wood's ARK funds and Nancy Pelosi's household. The broad rally reflects growing Wall Street conviction that artificial intelligence is moving from a research experiment to a revenue-generating part of the pharmaceutical and diagnostics value chain.
The catalysts were concrete. Novo Nordisk announced a collaboration with Anthropic on September 16 to apply the Claude Science model to drug discovery and research workflows. At the same time, Tempus AI offered a clearer reimbursement outlook, giving investors a more immediate line of sight to monetization beyond long-term drug development timelines. Together, the developments are forcing a reassessment of which AI healthcare businesses can convert rising adoption into sustainable earnings.
Why big pharma is betting on AI
Drug development has always been slow and expensive. Moving from target discovery through candidate screening to clinical trials takes years, and most molecules fail. AI compresses parts of that process: Data feeds predictive models, models guide candidate design, and experimental results loop back to refine the next round of predictions.
Novo Nordisk's Anthropic deal shows how large drugmakers are embedding AI into research infrastructure. Eli Lilly has been expanding its own AI-enabled development work. For these companies, the payoff comes in three forms: faster identification of promising targets from large biomedical datasets, fewer expensive dead ends in the lab, and broader pipelines that combine computing power with scientific expertise.
AI is becoming part of the competitive foundation for pharmaceutical R&D. The question for investors is which parts of the healthcare ecosystem are positioned to benefit first and most durably.
Six segments of the AI healthcare value chain
AI drug discovery remains the most visible opportunity. Companies like Absci Corp, Recursion Pharmaceuticals, and Schrodinger are building computationally driven research platforms where model predictions directly inform lab experiments. Tempus AI supports this work through clinical data and analytics capabilities that complement its diagnostics business. The broader biotech landscape includes Moderna, BioNTech, Beam Therapeutics, and CRISPR Therapeutics, though their reliance on AI varies considerably. The core challenge is translating computational hits into experimentally validated drug candidates.
Early detection and precision diagnostics represent a nearer-term commercial use case. Guardant Health focuses on liquid biopsy for cancer detection. Tempus AI combines clinical and molecular data with analytics to support treatment selection. Natera, Exact Sciences, and GeneDx Holdings operate across screening, diagnosis, and disease monitoring. AI's ability to find patterns in medical images, genomic tests, and other large datasets is pushing the field toward earlier detection and more personalized treatment plans.
Multi-omics and clinical data infrastructure underpins everything else. AI models need high-quality biological inputs. Illumina and 10x Genomics supply sequencing and analysis tools. Veeva Systems provides software and data capabilities for life sciences. Twist Bioscience produces synthetic DNA for research. As computationally driven research scales, the tools that generate and manage reliable biological data grow more valuable. For professionals working in clinical settings, understanding how these data pipelines function is increasingly relevant, and targeted training like AI for Healthcare Courses can help bridge the gap between lab science and operational workflows.
Surgical robotics and medical devices bring AI into the treatment room. Intuitive Surgical leads in robotic-assisted procedures, while Stryker, Medtronic, and Zimmer Biomet are integrating advanced software and computer vision into existing device portfolios. The goal is to support clinicians with navigation and precision-control capabilities without displacing their central role in medical decisions.
Digital health and care platforms extend AI beyond hospitals. Hims & Hers Health, Teladoc Health, Doximity, and Omada Health are applying AI to patient communication, chronic-condition management, and administrative workloads. The shared thesis is that reducing routine care costs through automation frees clinical teams to focus on patients who need more attention.
Medical imaging and diagnostic support is one of the more established clinical AI adoption areas. GE HealthCare Technologies, RadNet, Heartflow, and Butterfly Network are embedding AI tools into CT and MRI analysis, radiology support, and lesion identification. Because these tools slot into existing hospital systems and reimbursement frameworks, they offer a comparatively straightforward path to adoption and productivity gains. For administrative and billing professionals, the shift toward AI-assisted diagnostics has direct implications for coding and revenue cycle management, an area covered in depth by the AI for Medical Billers learning path.
Why this matters for healthcare professionals
AI is moving from a supporting research tool into the operational infrastructure of drug development, diagnostics, and care delivery. For clinicians, that means workflows will increasingly include AI-assisted imaging analysis, treatment selection support, and patient monitoring tools - not as replacements, but as embedded components of existing systems. For administrators and billers, the rise of AI-driven diagnostics and precision medicine will change coding complexity and reimbursement patterns. The professionals who understand how these tools work, what data they depend on, and where their limitations lie will be better positioned as the technology becomes standard practice across the healthcare system.
Your membership also unlocks:
